Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||CD274 positive|
|Therapy||Capecitabine + HX008 + Oxaliplatin|
|Indication/Tumor Type||gastroesophageal junction adenocarcinoma|
|Response Type||not predictive|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CD274 positive||gastroesophageal junction adenocarcinoma||not predictive||Capecitabine + HX008 + Oxaliplatin||Phase I||Actionable||In a Phase Ib trial, treatment with HX008, Xeloda (capecitabine), and Eloxatin (oxaliplatin) combination therapy resulted in an objective response rate (ORR) of 75% (9/12) and disease control rate (DCR) of 83.3% (10/12) in CD274 (PD-L1)-positive gastric or gastroesophageal junction cancer patients, compared to an ORR and DCR of 66.7% (6/9) and 100% (9/9) respectively in CD274 (PD-L1)-negative patients; however, no difference was observed in progression-free survival (p=0.19) (PMID: 33457083).||33457083|
|PubMed Id||Reference Title||Details|
|(33457083)||Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial.||Full reference...|